- Home
- Publications
- Publication Search
- Publication Details
Title
Recent developments in adjunct therapies for type 1 diabetes
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 31, Issue 12, Pages 1311-1320
Publisher
Informa UK Limited
Online
2023-01-19
DOI
10.1080/13543784.2022.2159806
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Contrast Pattern Mining With the T1D Exchange Clinic Registry Reveals Complex Phenotypic Factors and Comorbidity Patterns Associated With Familial Versus Sporadic Type 1 Diabetes
- (2022) Erin M. Tallon et al. DIABETES CARE
- Mortality trends in type 1 diabetes: a multicountry analysis of six population-based cohorts
- (2022) Paz L. D. Ruiz et al. DIABETOLOGIA
- Metformin and carotid intima‐media thickness in never‐smokers with type 1 diabetes: The REMOVAL trial
- (2021) Joseph G. Timmons et al. DIABETES OBESITY & METABOLISM
- Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland
- (2021) Anita Jeyam et al. DIABETOLOGIA
- Efficacy and Safety of Liraglutide in Type 1 Diabetes by Baseline Characteristics in the ADJUNCT ONE and ADJUNCT TWO Randomized Clinical Trials
- (2021) Thomas Fremming Dejgaard et al. DIABETES OBESITY & METABOLISM
- Empagliflozin in Heart Failure with a Preserved Ejection Fraction
- (2021) Stefan D. Anker et al. NEW ENGLAND JOURNAL OF MEDICINE
- A literature review and meta-analysis of safety profiles of SGLT2 inhibitors in Japanese patients with diabetes mellitus
- (2021) Junichi Mukai et al. Scientific Reports
- Metformin and cardiorenal outcomes in diabetes: A reappraisal
- (2020) John R. Petrie et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial
- (2020) Nicklas J Johansen et al. Lancet Diabetes & Endocrinology
- Benefit:Risk Profile of Dapagliflozin 5 mg in the DEPICT ‐1 and ‐2 Trials in Individuals with Type 1 Diabetes and BMI ≥27 kg/m 2
- (2020) Chantal Mathieu et al. DIABETES OBESITY & METABOLISM
- Exenatide extended release in patients with type 1 diabetes with and without residual insulin production
- (2020) Kevan C. Herold et al. DIABETES OBESITY & METABOLISM
- Comparison of indirect markers of insulin resistance in adult patients with Double Diabetes
- (2020) Aldo Ferreira-Hermosillo et al. BMC Endocrine Disorders
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
- (2020) DIABETES CARE
- Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes: pooled 52‐week outcomes from the DEPICT ‐1 and ‐2 studies
- (2020) Moshe Phillip et al. DIABETES OBESITY & METABOLISM
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range
- (2019) Tadej Battelino et al. DIABETES CARE
- Efficacy and safety of ipragliflozin add‐on therapy to insulin in Japanese patients with type 1 diabetes mellitus: A randomized, double‐blind, phase 3 trial
- (2019) Kohei Kaku et al. DIABETES OBESITY & METABOLISM
- Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
- (2019) Hertzel C Gerstein et al. LANCET
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2019) Mansoor Husain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Double diabetes: A distinct high‐risk group?
- (2019) Noppadol Kietsiriroje et al. DIABETES OBESITY & METABOLISM
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Sotagliflozin: A Review in Type 1 Diabetes
- (2019) Emma D. Deeks DRUGS
- Advances in technology for management of type 1 diabetes
- (2019) Roy W Beck et al. LANCET
- Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin‐pump‐treated patients with type 1 diabetes: The Lira Pump trial—a randomized, double‐blinded, placebo‐controlled trial
- (2019) Thomas F. Dejgaard et al. DIABETES OBESITY & METABOLISM
- SGLT2 inhibitors as adjunctive therapy for type 1 diabetes: balancing benefits and risks
- (2019) Simeon I Taylor et al. Lancet Diabetes & Endocrinology
- Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study
- (2018) John B. Buse et al. DIABETES CARE
- HbA1cand Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study
- (2018) Thomas Danne et al. DIABETES CARE
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial
- (2018) Chantal Mathieu et al. DIABETES CARE
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- (2018) Satish K. Garg et al. Diabetes Technology & Therapeutics
- Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study
- (2018) Paresh Dandona et al. DIABETES CARE
- Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials
- (2018) Julio Rosenstock et al. DIABETES CARE
- Addition of GLP‐1RA therapy to Insulin in C‐peptide Positive Patients With Type 1 Diabetes
- (2018) Nitesh D Kuhadiya et al. DIABETES OBESITY & METABOLISM
- Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk
- (2018) Julio Rosenstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
- (2018) Adrian F Hernandez et al. LANCET
- Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
- (2018) Stephen D. Wiviott et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections
- (2017) Roy W. Beck et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
- (2017) Rury R. Holman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes
- (2017) Satish K. Garg et al. NEW ENGLAND JOURNAL OF MEDICINE
- The effects of add-on exenatide to insulin on glycemic variability and hypoglycemia in patients with type 1 diabetes mellitus
- (2017) L.-l. Jiang et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial
- (2017) John R Petrie et al. Lancet Diabetes & Endocrinology
- Shift to Fatty Substrate Utilization in Response to Sodium–Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes
- (2016) Ele Ferrannini et al. DIABETES
- Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial
- (2016) Bo Ahrén et al. DIABETES CARE
- Addition of Liraglutide to Insulin in Patients With Type 1 Diabetes: A Randomized Placebo-Controlled Clinical Trial of 12 Weeks
- (2016) Nitesh D. Kuhadiya et al. DIABETES CARE
- Intensive Diabetes Treatment and Cardiovascular Outcomes in Type 1 Diabetes: The DCCT/EDIC Study 30-Year Follow-up
- (2016) DIABETES CARE
- Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
- (2016) Chantal Mathieu et al. DIABETES CARE
- Prevalence and comorbidities of double diabetes
- (2016) S.R. Merger et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The efficacy and safety of DPP4 inhibitors in patients with type 1 diabetes: A systematic review and meta-analysis
- (2016) Heming Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Dapagliflozin as Additional Treatment to Liraglutide and Insulin in Patients With Type 1 Diabetes
- (2016) Nitesh D. Kuhadiya et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study
- (2015) Christian S. Frandsen et al. DIABETES CARE
- Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes
- (2015) Robert R. Henry et al. DIABETES CARE
- Role of Amylin in Type 1 and Type 2 Diabetes
- (2015) Laura Hieronymus et al. DIABETES EDUCATOR
- Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison
- (2015) J. A. McKnight et al. DIABETIC MEDICINE
- Effect of Metformin Added to Insulin on Glycemic Control Among Overweight/Obese Adolescents With Type 1 Diabetes
- (2015) Ingrid M. Libman et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Estimated Life Expectancy in a Scottish Cohort With Type 1 Diabetes, 2008-2010
- (2015) Shona J. Livingstone et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion
- (2015) Caroline Bonner et al. NATURE MEDICINE
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
- (2015) Marc A. Pfeffer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Insulin resistance in type 1 diabetes: what is ‘double diabetes’ and what are the risks?
- (2013) S. J. Cleland et al. DIABETOLOGIA
- Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes
- (2013) William B. White et al. NEW ENGLAND JOURNAL OF MEDICINE
- Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
- (2013) Benjamin M. Scirica et al. NEW ENGLAND JOURNAL OF MEDICINE
- Risk of Cardiovascular Disease and Total Mortality in Adults with Type 1 Diabetes: Scottish Registry Linkage Study
- (2012) Shona J. Livingstone et al. PLOS MEDICINE
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual -Cell Function
- (2011) U. Kielgast et al. DIABETES CARE
- GIP and GLP-1, the two incretin hormones: Similarities and differences
- (2010) Yutaka Seino et al. Journal of Diabetes Investigation
- Pramlintide in the Treatment of Diabetes Mellitus
- (2008) Steve Edelman et al. BIODRUGS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started